Reach Us +441474556909
Single Cell Proteomics On A Multiplexed Nanosystem Platform | 6631
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Single cell proteomics on a multiplexed nanosystem platform

International Conference and Exhibition on Nanotechnology & Nanomedicine

Jun Wang

Accepted Abstracts: J Nanomedic Nanotechnol

DOI: 10.4172/2157-7439.S1.08

Cells in a tumor usually respond differentially to either conventional chemotherapy or targeted drug treatment, which leads to failure of cancer therapy. Thus, biological information from single cells is highly demanded in consideration of heterogeneity of a tumor sample. However, function assay of single cells through proteome profiling in a large population has been extremely difficult due to low abundance of most of proteins in a single cell. Here we introduce a high-throughput, multiplexed nanosystem to profile single cell proteome, either secretome or cytoplasmic phosphoproteome (Figure 1). We show each chamber with 0.1 nano-liter encapsulates one cell, and count as low as 100 molecules per cell. 8-24 phosphoproteins or cytocykine/chemokine in single cells are quantified. T cell secretome has been profiled using the nanosystem platform, and subsets of a healthy donor sample are identified. We also demonstrate to use the nanosystem to investigate PI3K signaling pathway and identify signal flux in GBM cell lines. We find P-ERK pathway and P-Akt1 pathway coordinately promote proliferation of U87 EGFR VIII cells, which may explain high malignancy of GBM cancer with EGFR VIII expression
Dr. Jun Wang joint NCI Alliance - Nanosystems Biology Cancer Center at California Institute of Technology as a postdoctoral fellow upon completion of his Ph.D in 2010 from Purdue University. He is also a research staff in UCLA School of Medicine. He has published more than 20 peer reviewed journal papers, with most of them at the interface of nano/micro technology and proteomics. He is also an active referee for journals such as Chemical Communications, Journal of Materials Chemistry